For the Quarter Ending December 2025
APAC
• In India, the Oxcarbazepine Price Index fell by 2.48% quarter-over-quarter, reflecting surplus merchant supply pressure.
• The average Oxcarbazepine price for the quarter was approximately USD 53558.69/MT, per regional spot sources.
• Oxcarbazepine Spot Price firmed while the Price Index reflected tighter intermediate inflows and stabilizing demand.
• Oxcarbazepine Price Forecast indicates modest firmness near term as demand recovery offsets sporadic feedstock arrivals.
• Oxcarbazepine Production Cost Trend shows pressure from bromo-acetophenone and packaging energy inflation further compressing margins.
• Oxcarbazepine Demand Outlook remains positive as formulators restock for Q1 tenders, supporting measured offtake growth. Oxcarbazepine Price Index volatility eased as inventories normalized and export schedules limited immediate upward pressure.
• Major producers ran near-nameplate capacity while smooth port operations helped maintain stable spot availability regionally.
Why did the price of Oxcarbazepine change in December 2025 in APAC?
• Domestic formulators accelerated purchases ahead of Q1 tenders, tightening spot availability and marginally supporting ex-works offers.
• Longer customs clearances for Chinese intermediates delayed feedstock arrivals, constraining immediate production and tightening merchant supply.
• Elevated intermediate and energy costs compressed margins, prompting producers to withhold discounts and maintain firmer pricing.
North America
• Regional price indices softened slightly over the quarter due to cautious restocking and moderate merchant supply.
• Spot prices firmed modestly in certain regions as inventories tightened and formulators adjusted procurement.
• Import logistics and customs processing influenced short-term supply flows.
• Formulators and hospitals restocked conservatively, awaiting clarity on Q1 procurement cycles.
• Demand remained stable but measured, preventing sharp price swings.
• Near-term outlook indicates stable to mild firmness, supported by consistent production and normalized inventories.
• Export and import schedules are expected to moderate volatility over the next quarter.
Why December 2025 Prices Changed
• Moderate demand and inventory management limited price momentum.
• Logistics and intermediate supply fluctuations affected availability and supported cautious price adjustments.
Europe
• Europe’s price index remained broadly stable with minor softening in markets facing surplus merchant supply.
• Spot prices varied regionally, firming slightly where inventories tightened.
• Formulators and hospitals undertook measured restocking ahead of Q1 tenders, supporting modest offtake growth.
• Tender cycles and healthcare budgets influenced demand stability across EU markets.
• Near-term forecast suggests stable to mildly firm pricing, as normalized inventories offset sporadic intermediate arrivals.
• Volatility is expected to remain low, supported by balanced supply-demand dynamics.
Why December 2025 Prices Changed
• Moderate demand and controlled restocking prevented sharp price increases.
• Delayed intermediates and higher energy costs limited discounting and maintained slight price firmness.
For the Quarter Ending September 2025
APAC
• In India, the Oxcarbazepine Price Index fell by 15.03% quarter-over-quarter, reflecting destocking and oversupply pressures.
• The average Oxcarbazepine price for the quarter was approximately USD 54919.74/MT measured across Vadodara-origin contracts.
• Oxcarbazepine Spot Price weakened in September as distributors discounted to reduce elevated national inventory levels.
• Oxcarbazepine Production Cost Trend rose from higher solvent and intermediate prices alongside modest INR depreciation.
• Oxcarbazepine Demand Outlook stayed weak as formulators postponed purchases amid monsoon and year-end inventory adjustments.
• Oxcarbazepine Price Forecast signals mild recovery as fiscal year-end restocking supports tighter availability into Q4.
• Oxcarbazepine Price Index volatility reflected shipment delays, container scarcity, and selective producer discipline on volumes.
• Export demand softened, pressuring domestic margins while traders aggressively liquidated stocks to maintain cash flow.
Why did the price of Oxcarbazepine change in September 2025 in APAC?
• Elevated inventories and dealer destocking in September amplified downward pressure on domestic Oxcarbazepine Price Index.
• Weak downstream demand and fiscal-year purchasing pauses reduced offtake, depressing Oxcarbazepine Spot Price momentum significantly.
• Rising solvent costs and INR depreciation increased Oxcarbazepine Production Cost Trend, sellers discounted protecting liquidity.
North America
• In the United States, the Oxcarbazepine Price Index declined, pressured by muted pharmaceutical formulation activity and heavy distributor inventories.
• Spot prices softened in September as contract buyers delayed offtakes amid slower API consumption and inventory balancing.
• The Oxcarbazepine production cost trend edged higher due to elevated solvent input costs and marginal increases in energy rates.
• Demand outlook remained weak as generic drug manufacturers minimized purchases, anticipating year-end price normalization.
• Price volatility stayed contained, supported by stable logistics, steady feedstock availability, and balanced supply discipline among key producers.
• Export orders into Canada and Mexico were limited, further weighing on domestic margins.
• Currency stability and lower freight costs limited pressure, maintaining a narrow trading range through late Q3.
Europe
• In Europe, the Oxcarbazepine Price Index fell further driven by subdued demand from formulation hubs.
• Spot prices weakened across key markets as distributors offered discounts to liquidate slow-moving inventories.
• The Oxcarbazepine production cost trend increased marginally amid higher energy tariffs and elevated intermediate costs.
• Demand outlook stayed bearish, with most formulators deferring purchases amid persistent inflationary pressure and weak export orders.
• Currency appreciation of the Euro versus the USD reduced import costs slightly, adding mild downward pressure on landed prices.
• Logistics and supply chain operations remained steady, preventing sharp supply disruptions or speculative price movements.
• Producer discipline and inventory clearance strategies defined pricing behavior through the end of September.
For the Quarter Ending June 2025
North America
• The Oxcarbazepine market in North America showed a downward trend throughout Q2 2025, mirroring the Indian market's overall decline with. Spot prices softened gradually, closing June around USD 64,700 per metric ton as supply outpaced demand amid subdued buying sentiment.
• Oxcarbazepine Production cost trends indicated slight decreases due to improved raw material sourcing and efficiency gains, even as elevated regulatory compliance expenses maintained moderate cost pressures.
• Oxcarbazepine Demand outlook within the quarter reflected cautious procurement patterns from pharmaceutical formulators, influenced by several market uncertainties and inventory surpluses resulting from muted end-user uptake of neurological treatments.
• The Oxcarbazepine spot price experienced continued downward pressure in June, with inventories rebuilt across distribution channels and conservative purchasing in response to forecasted price declines for the next quarter.
• Oxcarbazepine Supply chain reliability improved, facilitating regular API arrivals, yet manufacturers preferred limited contract expansions due to visibility concerns around demand and cost volatility.
• Oxcarbazepine Export demand from North American generic drug manufacturers to emerging markets softened, partially influenced by global pricing competition and procurement rescheduling.
• Cost pressures from energy and labor remained stable, preventing drastic fluctuations in production costs but hindering any major price recovery initiatives.
• The projected price forecast for the next quarter suggests a continuation of current soft pricing, with only marginal corrections expected as market players anticipate demand normalization post-inventory adjustments.
• Oxcarbazepine Manufacturing units focused on operational adjustments to optimize yield as API suppliers managed excess production capacities while maintaining compliance with US FDA standards.
• Overall, North America’s Oxcarbazepine market reflects a cautious stance, with downward trending prices consistent with India’s trend, stable production cost variables, and a demand outlook tempered by slow uptake and strategic stock management.
Asia-Pacific (APAC)
• The APAC Oxcarbazepine market demonstrated a mostly stable to slightly upward trajectory over Q2 2025, with the spot price averaging around USD 64483/MT by June with price changes oscillated narrowly around 0.80%, influenced by nuanced supply-demand push and pull.
• Oxcarbazepine Production cost trends showed variable behavior, with raw material availability constrained intermittently by regional logistical challenges and price inflation, particularly fuelled by Chinese intermediate shortages.
• Oxcarbazepine Demand outlook within Q2 was largely positive, supported by robust formulation activity in epilepsy and neurological disorder therapeutics and growing export orders, especially for generic producers targeting emerging markets.
• June 2025 saw a strong rebound in Oxcarbazepine prices amid heatwave disruptions and increased production costs, with spot prices edging higher as manufacturers faced batch delays and elevated solvent expenses.
• Export momentum from APAC Indian manufacturers sustained firm levels, driven by consistent orders from Southeast Asia, Africa, and Latin America, reinforcing firm pricing despite raw material cost pressures.
• The impact of regional climate conditions on production phases notably raised purification costs and triggered cautious stockpiling, reinforcing upward movements in spot pricing.
• Oxcarbazepine Price forecasts for the next quarter presume sustained elevated levels owing to ongoing supply constraints, expected raw material inflation, and persistent global demand for neurological APIs.
• Oxcarbazepine Production cost trends also reflected currency fluctuations, particularly the Indian Rupee depreciation, which augmented input costs for intermediates and logistics services.
• Downstream procurement behavior remained proactive, with formulators increasing API intake anticipating tighter supply and higher costs in H2 2025, thus sustaining demand strength.
• Overall, the APAC Oxcarbazepine market showcases resilient demand coupled with supply-side challenges that have maintained spot price stability and an optimistic outlook for pricing in the upcoming quarter.
Europe
• Europe’s Oxcarbazepine market paralleled the Indian trend with a persistent downward trajectory throughout Q2 2025, registering an average price witnessing a downward trend. Spot prices retreated in June to near €65,000/ton as importers grappled with inventory surpluses and subdued pharmaceutical demand.
• Oxcarbazepine Production cost trends indicated a slight easing due to better integration of advanced manufacturing technologies; however, regulatory compliance and energy costs maintained moderate pricing pressure.
• Oxcarbazepine Demand outlook exhibited conservative purchasing patterns, influenced by cautious hospital and pharmaceutical procurement cycles amid tightening healthcare budgets and regulatory hurdles.
• June witnessed a continuation of price softness, as market participants closely monitored global supply dynamics and delayed replenishment to optimize cost structures.
• European manufacturers faced challenges incorporating fluctuating raw material availability with the necessity for stringent GMP standards, influencing production costs but failing to prevent price declines.
• The Oxcarbazepine price forecast for the next quarter is muted, with expectations pointing toward stable to slightly lower spot prices, contingent on managing supply chain uncertainties and demand variability.
• Export dependence on global neurological drug markets remained steady but faced headwinds from slower growth in key consumer regions, affecting overall Oxcarbazepine consumption.
• Strategic production shifts focusing on cost optimization sought to mitigate margin erosions caused by shrinking order volumes and pricing pressures.
• Demand signals indicated continued downward adjustment cycles amid inventory recalibration, with formulators prioritizing existing stock utilization over fresh API procurement.
• In summary, Europe’s Oxcarbazepine scene remains challenged by weak demand coupled with cautious pricing strategies, maintaining consistent downward price trends reflecting Indian market influences and an uncertain demand outlook for the immediate future.
For the Quarter Ending March 2025
North America
In North America, the Oxcarbazepine API market saw a modest upward push in January 2025, fueled by increased demand for mental health and neurological treatments. Pharmaceutical manufacturers actively procured Oxcarbazepine to ensure sufficient inventory levels for the upcoming production cycles. Regulatory stability and higher healthcare funding in the United States and Canada supported procurement activities, while logistical improvements helped maintain smooth supply chains across major distribution hubs.
By February, however, market dynamics began to shift. Prices started to ease as stock levels among major formulators and distributors rose sharply following aggressive procurement in the previous month. Weakening downstream demand, combined with competitive pressures from domestic and international suppliers, led to modest price declines. Buyers became more selective, seeking discounts and renegotiating contracts in anticipation of further price softening. Additionally, fluctuations in raw material availability, particularly for fermentation-derived intermediates, added complexity to sourcing strategies.
The price weakening extended into March, closing the quarter on a softer note. Buyer caution remained high, and many preferred to delay procurement amid expectations of even lower prices ahead. Oversupply in the regional market, coupled with muted demand growth, pushed suppliers to offer further concessions. As a result, North America ended Q1 2025 with a bearish Oxcarbazepine market sentiment.
Asia Pacific
The Indian Oxcarbazepine API market showed a mixed performance in Q1 2025. In January, prices moved steadily upward after a prolonged period of correction, supported by rising pharmaceutical manufacturing activities and higher demand for neurological and cardiovascular treatments. Improved regulatory stability, government incentives, and better logistics further strengthened market sentiment. A strong Manufacturing PMI reading of 57.7 and heightened international demand enabled Indian exporters to negotiate higher prices, reinforcing India’s position as a key supplier in the global pharmaceutical sector.
However, by February, the market reversed its trajectory and entered a period of price decline. Sluggish demand from the pharmaceutical sector, along with excessive inventories among formulators and traders, weighed heavily on prices. Supply chain disruptions, fluctuating raw material costs, and a depreciation of the Indian Rupee further dampened buyer sentiment.
The downward trend extended into March 2025 as well, marking the third consecutive month of declining prices. Demand remained weak, with buyers maintaining a cautious stance and delaying major purchases in anticipation of better deals. Persistent oversupply and competitive pricing among suppliers continued to depress market fundamentals, closing the quarter on a bearish note.
Europe
The European Oxcarbazepine API market demonstrated a mixed trend in Q1 2025. In January, prices remained relatively firm, supported by steady pharmaceutical production levels and moderate demand from neurological and psychiatric drug manufacturers. Regulatory consistency and sustained healthcare investments across key European countries maintained stable procurement activities, helping prices stay elevated. However, supply chains continued to experience minor disruptions due to transportation delays and sourcing challenges for key intermediates, mildly limiting product availability.
In February, prices across Europe began to soften as demand growth failed to keep pace with rising stock levels. Formulators, having secured inventories earlier, slowed down new purchases, exerting downward pressure on supplier quotations. Meanwhile, the appreciation of the Euro slightly eased the cost burden of imported raw materials, allowing manufacturers to offer more competitive pricing. Competitive pressure among regional traders further contributed to price reductions, with buyers negotiating favorable contracts amid weakening sentiment.
March witnessed a continuation of the downward price trend as sluggish end-user demand persisted. Buyers in Europe adopted a cautious purchasing approach, preferring to exhaust existing inventories before committing to new orders. Despite some seasonal demand in certain therapeutic segments, the market remained oversupplied, forcing suppliers to offer discounts and promotional pricing to stimulate slow-moving sales.
